loratadine has been researched along with thyroxine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Auld, DS; Austin, CP; Huang, R; Moeller, TA; Sakamuru, S; Shinn, P; Shukla, SJ; Vanleer, D; Xia, M | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, T; Forman, BM; Lin, W; Yu, DD | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baskan, EB; Budak, F; Erturk, E; Gul, OO; Hacioglu, S; Imamoglu, S; Kiyici, S | 1 |
1 review(s) available for loratadine and thyroxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for loratadine and thyroxine
| Article | Year |
|---|---|
Effect of levothyroxine treatment on clinical symptoms and serum cytokine levels in euthyroid patients with chronic idiopathic urticaria and thyroid autoimmunity.
Topics: Adolescent; Adult; Autoimmune Diseases; Chi-Square Distribution; Chronic Disease; Drug Combinations; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Hypothyroidism; Interferon-gamma; Interleukin-10; Loratadine; Male; Middle Aged; Prospective Studies; Thyroxine; Treatment Outcome; Tumor Necrosis Factor-alpha; Urticaria; Young Adult | 2010 |
4 other study(ies) available for loratadine and thyroxine
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Identification of clinically used drugs that activate pregnane X receptors.
Topics: Animals; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Hep G2 Cells; Hepatocytes; Humans; Pharmaceutical Preparations; Pregnane X Receptor; Rats; Receptors, Steroid; Small Molecule Libraries; Species Specificity; Structure-Activity Relationship; Xenobiotics | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
Topics: Biological Assay; Drug Discovery; Fluoresceins; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Gene Expression Regulation; Isoxazoles; Molecular Structure; Protein Binding; Receptors, Cytoplasmic and Nuclear | 2013 |